Exclusive Summary

• A standard-of-care 3rd/4th-line therapy for high-prevalence Metastatic Colorectal and Gastric Cancers with substantial global demand.
• Ideally timed for market entry as the innovator (Lonsurf) faces patent cliffs globally, offering a 'Golden Window' for generic launches.
• Strongly recommended by NCCN and ESMO guidelines, ensuring high clinical acceptance and physician prescribing confidence.
• Offers a high-barrier-to-entry generics profile (combination formulation) with significant cost advantages over the expensive innovator product.
• Ready for distribution with competitive pricing, suitable for capturing market share in both regulated and emerging markets.

Asset Materials

Contact Us for Full Materials